Table 2.
Median progression-free and overall survival estimates for the entire study population and by EGFR FISH status
| Analysis Group | Outcome (mos) | All Patients Median (95% CI) |
EGFR-FISH+ Median (95% CI) |
EGFR-FISH-NP Median (95% CI) |
|
|---|---|---|---|---|---|
|
| |||||
| All Patients
|
OS
|
Cetuximab Arm | 10·9 (9·5–12·0)
|
13·4 (11·5–14·8)
|
9·5 (8·2–10·9)
|
| Control Arm | 9·2 (8·7–10·3) | 9·8 (8·7–12·1) | 8·9 (8·4–10·2) | ||
|
| |||||
|
|
PFS | Cetuximab Arm
|
4·6 (4·2–5·2)
|
5·4 (4·5–5·7)
|
4·4 (4 0–4 8)
|
| Control Arm | 4·5 (4 2–5·1) | 4·8 (3·9–5·5) | 4·3 (4·1–4·9) | ||
|
| |||||
| Bevacizumab | OS | Cetuximab Arm | 12·7 (10·9–13·4) | 15·9 (13·4–19·1) | 10·9 (9·1–12·5) |
| Control Arm | 11·6(10·5–13·6) | 13·2 (11·2–19·9) | 11·2 (9·9–13·0) | ||
| PFS | Cetuximab Arm | 5·7 (5·3–6·1) | 6·2 (5·7–8·0) | 5·4 (4·6–5·8) | |
| Control Arm | 5·9 (5·5–6·7) | 6·7 (5·7–8·0) | 5·6 (5·3–6·4) | ||
|
| |||||
| No Bevacizumab
|
OS | Cetuximab Arm
|
9·2 (8·1–10·9)
|
11·2 (8·6–12·9)
|
8·4 (7·2–10·3)
|
| Control Arm | 8·1 (7·2–8·7) | 8·7 (5·9–10·2) | 8·1 (7·2–8·6) | ||
|
| |||||
|
|
PFS | Cetuximab Arm
|
4·1 (3·5–4·4)
|
4·4 (3·8–5·2)
|
4·0 (3·1–4·3)
|
| Control Arm | 3·8 (3·1–4·2) | 3·7 (2·8–4·6) | 4·0 (3·0–4·2) | ||
|
| |||||
| Squamous Cell Histology | OS | Cetuximab Arm | 9·6 (8·2–11·5) | 11·8 (8·6–13·5) | 8·5 (6·4–10·4) |
| Control Arm | 8·0 (7·1–8·8) | 6·1 (4·2–8·7) | 8·4 (7·2–9·9) | ||
|
|
PFS | Cetuximab Arm
|
4·2 (3·7–4·6)
|
4·5 (3·8–5·2)
|
4·0 (2·9–4·5)
|
| Control Arm | 3·7 (2·8–4·3) | 2·8 (2·6–4·1) | 4·1 (3·0–4·8) | ||
|
| |||||
| Non-Squamous Histology
|
OS | Cetuximab Arm
|
11·2 (9·6–12·5)
|
14·3 (11·4–17·7)
|
10·0 (8·4–11·7)
|
| Control Arm | 10·2 (9·0–11·2) | 12·1 (9·7–13·8) | 9·2 (8·5–10·8) | ||
|
| |||||
|
|
PFS | Cetuximab Arm
|
5·1 (4·4–5·4)
|
5·7 (5·2–6·5)
|
4·6 (4·1–5·3)
|
| Control Arm | 4·9 (4·3–5·5) | 5·5 (4·6–6·1) | 4·5 (4·1–5·3) | ||
Footnote: mos = months, NP = non-positive (includes EGFR FISH negative and EGFR FISH status unknown).